Cognito Therapeutics Partners with Initiative to Replace “Dementia” Terminology Across Communications
Cognito Therapeutics Collaborates with Initiative to Replace the “D-Word,” Committing to Remove “Dementia” from All Communications Cognito Therapeutics, a late clinical-stage neurotechnology company focused on developing non-invasive therapies for neurodegenerative…
ReAlta Life Sciences Secures $40M Financing to Advance Pegtarazimod Phase 2 Program in HIE
ReAlta Life Sciences Completes Oversubscribed $40M Financing to Support Pegtarazimod Phase 2 Development in Hypoxic Ischemic Encephalopathy (HIE) ReAlta Life Sciences Inc. (“ReAlta”), a clinical-stage biopharmaceutical company focused on targeting…
United Therapeutics Corporation Receives U.S. Food and Drug Administration RMAT Designation for miroliverELAP® in Acute Liver Failure
United Therapeutics Corporation Receives U.S. Food and Drug Administration Regenerative Medicine Advanced Therapy (RMAT) Designation for miroliverELAP® in the Treatment of Acute Liver Failure United Therapeutics Corporation (Nasdaq: UTHR), a…
Aurion Biotech Initiates Phase 3 ASTRA Study of AURN001 for Corneal Edema
Aurion Biotech Initiates Dosing in Phase 3 ASTRA Study Evaluating AURN001 for Corneal Edema Secondary to Corneal Endothelial Dysfunction Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company…
VION Biosciences Completes Acquisition of CTL to Enhance Functional Immune Monitoring Capabilities
VION Biosciences Completes Acquisition of CTL, Bolstering Its Functional Immune Monitoring Capabilities VION Biosciences (“VION”), a life sciences company focused on building differentiated capabilities across research, diagnostics, and drug development…
Sidewinder Therapeutics Secures $137M Series B to Advance Bispecific ADCs in Cancer Development
Sidewinder Therapeutics Secures $137 Million Series B to Advance Precision Bispecific ADCs into Clinical Development for Cancer Sidewinder Therapeutics, a biopharmaceutical company focused on advancing next-generation antibody-drug conjugates (ADCs) for…
Merck Initiates Tender Offer for the Acquisition of Terns Pharmaceuticals, Inc.
Merck Launches Tender Offer to Acquire Terns Pharmaceuticals, Inc. Merck & Co., Inc., known as MSD outside the United States and Canada, has officially launched a cash tender offer through…
Allergan Aesthetics Launches Its Third Advanced AMI Training Center in Austin
Allergan Aesthetics Launches Its Third Advanced AMI Training Center in Austin Allergan Aesthetics, a leading global provider of aesthetic medicine solutions and part of AbbVie, has announced the opening of…
enGene Confirms Corporate Name Change to enGene Therapeutics Inc
enGene Confirms Corporate Name Change to enGene Therapeutics Inc enGene Therapeutics Inc., a clinical-stage biotechnology company focused on the development of non-viral genetic medicines, has announced that it will officially…
Biocon Launches Bosaya™ and Aukelso™ Denosumab Biosimilars in the U.S.
Biocon Announces U.S. Commercial Debut of Bosaya™ and Aukelso™, Its Denosumab Biosimilars Biocon Limited, a global innovation-driven biopharmaceutical organization, has announced the commercial launch of two denosumab biosimilars—Bosaya™ and Aukelso™—in…
Shionogi Showcases Real-World Fetroja Data at ESCMID 2026
Shionogi Highlights Real-World Effectiveness of Fetroja/Fetcroja Against MBL-Producing Enterobacterales at ESCMID Global 2026 Shionogi & Co., Ltd. has unveiled new real-world and surveillance data highlighting the clinical utility of cefiderocol…
Gilead to Acquire Tubulis, Boosting Oncology Pipeline with Next-Gen ADC Platform
Gilead to Acquire Tubulis to Enhance Oncology Portfolio with Potentially Best-in-Class ADC and Advanced Platform Gilead Sciences has announced that it has entered into a definitive agreement to acquire Tubulis…